Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Intercell Cuts Full-Year Sales, Earnings Forecast on Ixiaro

Oct. 16 (Bloomberg) -- Intercell AG cut its forecast for full-year sales and earnings by as much as 20 percent, citing lower-than-expected demand for its Ixiaro vaccine against Japanese Encephalitis.

The net loss will be between 20 million euros ($26 million) and 24 million euros this year, the Vienna-based company said in statement today. Product sales will be between 26.5 million and 28.5 million euros, according to Intercell.

The company is scheduled to report third-quarter results on November 7.

To contact the reporter on this story: Eva von Schaper in Munich at evonschaper@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.